Deca 300 300mg/ml 10ml Vial by GenTec

Usage

1. Inspect the vial before drawing: hold it against a light source to confirm the oil is clear, particle-free, and the stated amber or colourless colour is uniform — any cloudiness that persists at room temperature indicates a compromised formulation.
2. Warm the vial to approximately 37 °C (body temperature) by rolling it between your palms for 30–60 seconds; warm oil flows more easily through the draw needle and reduces injection-site discomfort caused by viscous oil pressure.
3. Cleanse the rubber septum with a 70 % isopropyl alcohol swab and allow it to dry fully — a wet septum can carry surface alcohol into the vial, potentially denaturing the ester.
4. Draw with an 18–21 gauge needle to aspirate oil efficiently; then replace with a sterile 23–25 gauge, 1–1.5 inch needle appropriate for the target intramuscular site (gluteus maximus, vastus lateralis, or deltoid for volumes ≤ 1 ml).
5. Inject slowly — approximately 1 ml per 10 seconds — to allow the oil depot to form gradually within the muscle belly rather than creating a pressure bolus that increases post-injection soreness.
6. Apply gentle pressure with a sterile swab post-injection (do not rub vigorously, as rubbing disperses the depot prematurely and may alter absorption kinetics); record the injection date and volume for tracking cumulative weekly dose against your protocol.

Warnings

Frequently asked questions

Why does injectable Nandrolone Decanoate have higher bioavailability than oral nandrolone?

Injectable Nandrolone Decanoate bypasses first-pass hepatic metabolism entirely, allowing close to 100% of the administered dose to reach systemic circulation. Oral nandrolone must pass through the gut wall and liver before entering the bloodstream, where enzymatic degradation can eliminate 60–90% of the compound. The decanoate ester's lipophilicity also supports stable depot formation at the injection site, sustaining release without repeated oral dosing.

What exactly is first-pass metabolism and how does it reduce oral androgen effectiveness?

First-pass metabolism occurs when an ingested compound is absorbed from the gastrointestinal tract into the portal vein and processed by the liver before reaching general circulation. Hepatic cytochrome P450 and other oxidative enzymes break down a large fraction of oral androgens at this stage. Oral compounds must be chemically modified — typically C-17α alkylation — to resist this degradation, but that modification brings hepatotoxicity risk that injectable Nandrolone Decanoate entirely avoids.

How does the absorption process differ between an intramuscular Nandrolone Decanoate injection and an oral steroid capsule?

After intramuscular injection, Nandrolone Decanoate forms an oil depot within muscle tissue. Tissue and plasma esterases hydrolyse the ester bond progressively, releasing free nandrolone directly into venous blood — bypassing portal circulation. An oral capsule, by contrast, must dissolve in gastric fluid, cross the intestinal epithelium, enter the portal system, and survive hepatic first-pass before active drug is available. The injectable route delivers bioavailable hormone faster and more completely.

How should a 300mg/ml Nandrolone Decanoate vial be drawn using an insulin syringe, and what volume represents a typical 300mg dose?

A 300 mg dose from GenTec Deca 300 at 300 mg/ml equals exactly 1.0 ml. Standard insulin syringes (1 ml capacity, typically 27–29 gauge) are generally too fine for viscous oil-based preparations; an 18–21 gauge draw needle is recommended to aspirate the oil, then swapped for a 23–25 gauge, 1–1.5 inch injection needle for intramuscular administration. Never use an insulin syringe as the injection needle for oil-based compounds.

How should a GenTec Deca 300 10ml vial be stored after it has been opened?

After the rubber stopper is first punctured, store the vial upright at room temperature (15–25 °C), away from direct light and heat sources. Do not refrigerate oil-based injectable solutions, as cold temperatures increase viscosity and may cause the oil to cloud or precipitate. Maintain strict aseptic technique on every draw, and discard the vial if particulate matter, unusual colour changes, or cloudiness that does not resolve at room temperature is observed. (2) angle_used

Manufacturer

GenTec's quality infrastructure centres on certification-level compliance rather than in-house manufacturing — a distinction that defines how the company approaches batch-release accountability. Products carrying the GenTec label are required to meet GMP standards as defined under EU Directive 2003/94/EC for medicinal product manufacture, with manufacturing-site audits forming the basis of ongoing supply-partner qualification. ISO-aligned quality management system documentation governs incoming API testing, in-process checks, and finished-product release criteria; HPLC quantitative analysis of active-ingredient concentration and LAL endotoxin batch testing are among the release-critical checkpoints applied to injectable products like Deca 300 before distribution. Certificate of Analysis documentation accompanies each batch, providing traceability between the production record and the concentration data printed on the vial label — a chain of evidence that underpins label-claim integrity for a 300 mg/ml product where dosing precision directly determines bioavailable drug delivery.